Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy:

Completed

Conditions studied: Epilepsy

In brief

To determine, in a randomized, parallel open-label fashion, compliance rates between once-daily extended-release divalproex sodium tablets (Depakote-ER®, Abbott Labs) versus multiple-daily dose valproic acid capsules (Depakene®, Abbott Labs) in an epilepsy population.

Key facts

Study ID

NCT00356018

Run by

Orlando Health, Inc.

People needed

5

Starts

2006-07-01

Expected to finish

2007-05-01

Last updated by the study team

2020-03-04

Who can join

Age: 16 and older, up to 99. Sex: any. Healthy volunteers: accepted.

Where it is running

• Orlando Regional Lucerne Hospital — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.